WWW - Posts tagged Vidaza at BloggingStocks

Vidaza posts

Celgene Remains in an Uptrend

Posted Dec 21st 2009 5:00PM by Joseph Lazzaro (RSS feed)
Filed under: Stocks to Buy

Celgene Corp.'s (CELG) stock has encountered resistance at $58, but I'm nevertheless reiterating my buy rating for the company's shares, first recommended on June 19, 2009, at a price of $46.94. Here's why:

Look for Celgene's FY2010 revenue to increase 20-23%, on top of a likely a 15-20% rise in FY2009, boosted by cancer treatments Revlimid's and Vidaza's sales. Further, pipeline candidates to treat psoriasis and small cell lung cancer are approaching late-stage study.

Continue reading Celgene Remains in an Uptrend

Time to scoop up some shares of Celgene

Posted Jun 19th 2009 5:00PM by Joseph Lazzaro (RSS feed)
Filed under: Stocks to Buy

Pharmaceutical company Celgene Corp., beaten down by Wall Street for the better part of 10 months, is now a Buy in these circles. Here's why:

Analysts now expect FY2009 revenue to increase 15-18%, boosted by Revlimid and Vidaza sales. Further, pipeline candidates in psoriasis and small cell lung cancer are nearing late-stage study. The First Call FY2009/FY2010 EPS estimates for CELG are $2.04 to $2.65.

Continue reading Time to scoop up some shares of Celgene

Major mover: Pharmion (PHRM) jumps by half

Posted Aug 2nd 2007 1:27PM by Kelly Wu (RSS feed)
Filed under: Major Movement

Positive test results for Pharmion Corporation (NASDAQ: PHRM)'s drug Vidaza shot the global pharmaceutical firm's shares more than 50% higher in morning trading Thursday. Pharmion is currently the biggest percentage gainer on the NASDAQ.

Vidaza is said to significantly extend the life of patients with myelodysplastic syndrome. In a late-stage study, results showed that taking Vidaza extends the median survival of 15 months for those on conventional treatments to 24.4 months. Shortly before 1:30 p.m., Pharmion shares were trading at $37.60, up 52% from Wednesday's $24.64 close.